GlassScriptPhysician profile
Natalie J Baker
NPI 1174564082
$3,577.46
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $593 · 2021: $1,801 · 2022: $1,156 · 2023: $28.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.37 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $371.30 | 2020-2022 | |
| Lundbeck LLC | $354.80 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $283.88 | 2020-2022 | |
| Alkermes, INC. | $229.84 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $220.54 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.42 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $170.86 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.82 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $133.41 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $123.68 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $107.11 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $100.94 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $86.80 | 2020-2022 | |
| Neos Therapeutics, LP | $76.11 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $74.58 | 2020-2022 | |
| Eisai INC. | $70.14 | 2020-2021 | |
| Adlon Therapeutics L.P. | $57.96 | 2020-2021 | |
| Harmony Biosciences LLC | $57.09 | 2021-2022 | |
| Allergan, INC. | $55.44 | 2020 | |
| Arbor Pharmaceuticals, INC. | $43.99 | 2021-2022 | |
| Alfasigma USA, INC. | $41.84 | 2022 | |
| Bausch Health US, LLC | $29.57 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.